So 3F, this is one of those assets that could be i
Post# of 30029
What does today's collaboration tell us? Clearly, Biolife can consider 3F their own asset, they're just getting help with it. This merely advances its development. Chemia is no joke. I equate them with Theranostics. A serious scientific company, not big, but ambitious. They have decent size in employee count (approx 50) and facility. Revs unknown, but they do business.
From the LOI: Target Assets. SeD Biomed proposes to invest in one or more of the following biomedical assets described below and thereafter invest such biomedical assets into Amarantus.
If SeD invested in 3F, they must have come to an understanding with AMBS that this was the asset that was interesting, right? And why would they reach and understanding if conditions were unable to be met?